- Trial phase
- Preclinical (IND-enabling)
- Time to market
- Unknown, still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
- Why 4/10
- MT-001 is a preclinical-stage asset. The nearest catalyst is the first-in-human regulatory filing (IND/CTA) expected mid-2026, a procedural milestone, not a data readout. Phase 2a proof-of-concept data isn't due until 2028 (>12 months away). The stock already repriced ~100%+ on the May 2026 reverse-merger announcement. A regulatory filing is unlikely to drive a major second leg, hence 4.
MT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.
Price Chart
Executive Summary
MT-001 is a preclinical-stage anti-PACAP monoclonal antibody for migraine prevention, discovered by Paragon Therapeutics and being advanced by Mentari Therapeutics. Mentari is reverse-merging into InMed Pharmaceuticals (NASDAQ: INM) in a deal backed by a $290M PIPE led by Fairmount that funds operations through 2028. The PACAP pathway was recently validated by Lundbeck's bocunebart, which succeeded in Phase 2b trials. However, MT-001 has no human data yet; first-in-human filings are expected mid-2026 and Phase 2a proof-of-concept data not until 2028. Competition is intensifying from Lundbeck (more advanced), Slate Medicines ($130M funded), and Vedana. The stock surged ~100%+ on the merger news, but MT-001 itself is years from a value-changing catalyst.
How It Works
MT-001 is a monoclonal antibody (a manufactured protein that mimics the immune system's ability to fight targets) designed to block PACAP, a signaling protein involved in migraine. PACAP is a newly validated target that works through a different biological pathway than the current standard-of-care CGRP inhibitors. By blocking PACAP, MT-001 aims to prevent migraine attacks, especially in the ~40-50% of patients who don't respond well to existing anti-CGRP therapies. It is designed for subcutaneous (under-the-skin) injection for patient convenience.
Trial Status
MT-001 is in preclinical development. Discovered by Paragon Therapeutics, it has demonstrated equal or superior in vitro potency vs. benchmark antibodies, with favorable pharmacokinetic profiles in non-human primates. First-in-human regulatory filings (IND/CTA) are expected mid-2026. Phase 1 trials would follow, with Phase 2a proof-of-concept data projected for 2028.
The Two-Sided Case
Upcoming Catalysts
- Mid-2026: First-in-human regulatory filing (IND/CTA) for MT-001
- By Dec 31, 2026: Expected close of InMed-Mentari reverse merger, new Nasdaq ticker
- Q1 2027: Phase 1 healthy volunteer data for MT-002 (bispecific)
- 2028: Phase 2a proof-of-concept data for MT-001
Source Filing
The SecBot filing or press-release report that triggered this drug report:
InMed Pharmaceuticals Inc. S-4 INM ·Originating report